1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Venezuela Pharmaceuticals and Healthcare Report Q3 2016

Venezuela Pharmaceuticals and Healthcare Report Q3 2016

  • June 2016
  • -
  • Business Monitor International
  • -
  • 101 pages

Includes 3 FREE quarterly updates

BMI View: Multinational pharmaceutical companies will increasingly experience the negative currencyimpact of Venezuela's recent reforms which will allow for much more rapid currency depreciation for theSimadi rate. It is our long-standing view that currency devaluations, price controls, import and foreigncurrency controls and hyper inflation, as well as other structurally distorting policies in Venezuela, willcontinue to plague the country's pharmaceutical market in 2016.Headline Expenditure Projections

- Pharmaceuticals: VEB88.7bn (USD3.0bn) in 2015 to VEB259.6bn (USD950mn) in 2016; +192.6% inlocal currency terms and -68.6% in US dollar terms. Forecast has been maintained with Q216 in localcurrency terms.

- Healthcare: VEB297.3bn (USD10.2bn) in 2015 to VEB838.7bn (USD12.9bn) in 2016; +182% in localcurrency terms and +27.0% in US dollar terms. Forecast has been revised upward from Q216 due tonewly released historical data.

Table Of Contents

Venezuela Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Venezuela 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Venezuela 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Venezuela 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Venezuela 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Venezuela 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Venezuela 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Venezuela 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Venezuela 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Venezuela 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Venezuela 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Venezuela 2014-2020) 29
Industry Risk/Reward Index 30
Americas Risk/Reward Index 30
Venezuela Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 37
Intellectual Property Issues 37
Pricing Regime 41
Reimbursement Regime 43
Market Overview 45
Healthcare Sector 45
Table: Healthcare Resources (Venezuela 2010-2015) 48
Table: Healthcare Personnel (Venezuela 2010-2015) 49
Table: Healthcare Activity (Venezuela 2010-2015) 49
Research and Development 51
Clinical Trials 52
Epidemiology 53
Competitive Landscape 56
Research-Based Industry 56
Generic Drugmakers 58
Pharmaceutical Distribution 59
Pharmaceutical Retail Sector 61
Company Profile 63
Boehringer Ingelheim 63
Calox International 65
Elmor 67
GlaxoSmithKline 70
Grupo Farma 73
Merck and Co 76
Novartis 79
Pfizer 82
Sanofi 86
Strides Latina (Sumifarma) 88
Demographic Forecast 90
Demographic Outlook 2015 90
Table: Population Headline Indicators (Venezuela 1990-2025) 91
Table: Key Population Ratios (Venezuela 1990-2025) 91
Table: Urban/Rural Population and Life Expectancy (Venezuela 1990-2025) 92
Table: Population By Age Group (Venezuela 1990-2025) 92
Table: Population By Age Group % (Venezuela 1990-2025) 93
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Index Methodology 99
Index Overview 100
Table: Pharmaceutical Risk/Reward Index Indicators 100
Indicator Weightings 101

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • May 2016
  • by Global Data

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024 Summary Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired ...

Asthma Pricing, Reimbursement, and Access

Asthma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the asthma market will be fueled by the introduction of new and expensive biologics, but companies will have to navigate access restrictions imposed by payers concerned about budget impact. This ...

Multiple Myeloma Pricing, Reimbursement, and Access

Multiple Myeloma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the multiple myeloma market will be spurred by the approval of novel drugs and the increasing role of combination therapy, but risk-sharing agreements will be key to entry into increasingly restrictive ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.